Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Drug Interactions
  • Dosage

Brand Names


Austria: Optiray; Belgium: Optiject, Optiray; Czech Republic: Optiray; Denmark: Optiray; Finland: Optiray; France: Optiject, Optiray; Germany: Optiject, Optiray; Greece: Optiray; Hungary: Optiray; Ireland: Optiray; Italy: Optiray; Luxembourg: Optiject; Netherlands: Optiray; Poland: Optiray; Romania: Optiray; Slovakia: Optiray; Spain: Optiray; Sweden: Optiray.

North America

Canada: Optiray; USA: Optiray.


Japan: Optiray.

Drug combinations


Ioversol: C~18~H~24~I~3~N~3~O~9~. Mw: 807.11. (1) 1,3-Benzenedicarboxamide, N,N’-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)(2-hydroxyethyl)amino]-2,4,6-triiodo-; (2) N,N’-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-triiodoisophthalamide. CAS-87771-40-2 (1987).

Pharmacologic Category

Diagnostic Agents; Imaging Agents; Iodinated Contrast Media. Radiological/Contrast Media (Nonionic, Low Osmolality). (ATC-Code: V08AB07).

Mechanism of action

Therapeutic use

Arteriography, angiography, angiocardiography, ventriculography, excretory urography, and venography procedures. Contrast-enhanced tomographic imaging.

Pregnancy and lactiation implications

Teratogenic effects not observed in animal studies. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis. Excretion in breast milk unknown (use caution).

Unlabeled use


Hypersensitivity to any component of the formulation. Not for intrathecal use.

Warnings and precautions



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart